2017 Federal Circuit Obviousness Decisions in Biopharma: 5 Takeaways
April 17, 2018
By: Ross Blau
Westlaw Journal
Ross Blau co-authored, "2017 Federal Circuit Obviousness Decisions in Biopharma: 5 Takeaways" with Jonathan Harris and Drew Hillier which was published by Westlaw Journal Medical Devices, Westlaw Journal Products Liability, Westlaw Journal Health Law, Westlaw Journal Pharmaceutical and Westlaw Journal Intellectual Property. The article discusses nuanced shifts in Federal Circuit opinions and the lessons that can be gleaned from them.
Click here to access the article.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
IPWatchdog Sixth Annual Live Conference
Speaking Engagement
Intellectual Property
ABA White Collar Crime Institute 2026
Speaking Engagement
GCR Live Cartels: 2026
Speaking Engagement
Antitrust
SCCE 14th Annual European Compliance & Ethics Institute
Speaking Engagement
Antitrust
Noerr Competition Day 2026
Speaking Engagement
Antitrust
Axinn Antitrust Insight: "New" HSR Form Remains in Effect For Now – Fifth Circuit Temporarily Freezes District Court Order that Vacated the New HSR Rule
Axinn Viewpoints
Antitrust
Consumer Brands CPG Legal Forum 2026
Speaking Engagement
NBA CLS 39th Annual Corporate Counsel Conference
Sponsorship
Antitrust
University of Pennsylvania Journal of Business Law Annual Symposium 2026
Speaking Engagement
Antitrust
Chambers Recognizes Axinn’s Antitrust Practice in 2026 Global Rankings — With New Recognition in Cartel Category
Awards & Recognitions
Antitrust
